Cardiac and Renal SARS-CoV-2 Viral Entry Protein Regulation by Androgens and Diet: Implications for Polycystic Ovary Syndrome and COVID-19

September 2021 in “ International Journal of Molecular Sciences ”

Samar Rezq, Alexandra M. Huffman, Jelina Basnet, Licy L. Yanes Cardozo, Damián G. Romero

androgens high-fat diet SARS-CoV-2 viral entry proteins Polycystic Ovary Syndrome PCOS ACE2 cellular proteases hyperandrogenism androgen receptor blockers HFD COVID-19 weight loss

Studysummary This study suggests that women with polycystic ovary syndrome may have an increased risk of COVID-19-related cardiac and renal complications, and that weight loss through lifestyle changes could help reduce these risks.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on mdpi.com →

Discuss this study in the Community →

Research cited in this study

8 / 8 results

research Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men

139 citations , December 2020 in “Cell Stem Cell”

Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.

research Clinical Symptoms of Hyperandrogenic Women Diagnosed with COVID-19

29 citations , October 2020 in “Journal of the European Academy of Dermatology and Venereology”

This article is a discussion piece that examines the clinical symptoms of hyperandrogenic women with COVID-19, without reporting new research findings.

research Androgen Sensitivity Gateway to COVID-19 Disease Severity

123 citations , May 2020 in “Drug Development Research”

This article argues that androgen sensitivity could be a key factor in the severity of COVID-19, suggesting that trials with anti-androgen agents may be warranted.

research What Does Androgenetic Alopecia Have to Do with COVID-19? An Insight into a Potential New Therapy

47 citations , April 2020 in “Dermatologic Therapy”

This letter discusses the potential connection between androgenetic alopecia and COVID-19, suggesting a possible new therapy, but it reports no new results.

Ethnicity, Obesity, and the Prevalence of Impaired Glucose Tolerance and Type 2 Diabetes in PCOS: A Systematic Review and Meta-Regression

research Ethnicity, Obesity, and the Prevalence of Impaired Glucose Tolerance and Type 2 Diabetes in PCOS: A Systematic Review and Meta-Regression

189 citations , March 2018 in “Human Reproduction Update”

This study reported that women with polycystic ovary syndrome had a higher prevalence of impaired glucose tolerance and type 2 diabetes, with variations influenced by ethnicity and obesity.

research The Androgen Excess and PCOS Society Criteria for the Polycystic Ovary Syndrome: The Complete Task Force Report

1540 citations , October 2008 in “Fertility and Sterility”

This review discusses the definition of polycystic ovary syndrome proposed by the AE-PCOS Society Task Force, emphasizing hyperandrogenism, ovarian dysfunction, and excluding related disorders, while noting potential variations needing more research.

Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline

research Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline

1744 citations , August 2006 in “The Journal of Clinical Endocrinology and Metabolism”

This review discusses definitions of polycystic ovary syndrome and reports no new clinical results; the authors support using modified 1990 NIH criteria and acknowledge ongoing evolution as research advances.

research Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome

4809 citations , January 2004 in “Fertility and Sterility”

This review discusses polycystic ovary syndrome, emphasizing its broad range of manifestations and associations with risks like type 2 diabetes and cardiovascular events, but reports no new clinical results.